Last reviewed · How we verify
Humanity and Health Research Centre — Portfolio Competitive Intelligence Brief
4 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| SOF+DCV | SOF+DCV | marketed | Other | |||
| SOF+PEG+RBV | SOF+PEG+RBV | marketed | Other | |||
| SOF+RBV | SOF+RBV | marketed | Direct-acting antiviral (DAA) combination | HCV NS5B RNA polymerase; viral replication machinery | Virology / Hepatology | |
| Tenofovir alafenamide(TAF) | Tenofovir alafenamide(TAF) | marketed | Nucleotide reverse transcriptase inhibitor (NtRTI) | HIV reverse transcriptase | Infectious Disease / Virology |
Therapeutic area mix
- Other · 2
- Infectious Disease / Virology · 1
- Virology / Hepatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Almaza Military Fever Hospital · 1 shared drug class
- Egyptian Liver Hospital · 1 shared drug class
- Federal University of São Paulo · 1 shared drug class
- French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
- HaEmek Medical Center, Israel · 1 shared drug class
- Hannover Medical School · 1 shared drug class
- ANRS, Emerging Infectious Diseases · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Humanity and Health Research Centre:
- Humanity and Health Research Centre pipeline updates — RSS
- Humanity and Health Research Centre pipeline updates — Atom
- Humanity and Health Research Centre pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Humanity and Health Research Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/humanity-and-health-research-centre. Accessed 2026-05-18.